The evolving world of GLP-1 agonist therapies for type 2 diabetes

The glucagon-like peptide-1 (GLP-1) agonist drugs have attractions as a treatment for type 2 diabetes since they positively alter a number of key pathophysiological defects. These include increasing insulin release, reducing glucagon release, slowing gastric emptying and reducing food intake. In num...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Therapeutic advances in endocrinology and metabolism 2010-04, Vol.1 (2), p.61-67
1. Verfasser:	Baynes, Kevin C R
Format:	Artikel
Sprache:	eng
Schlagworte:	Review
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!